For example, the engineered Escherichia coli Nissle 1917 strain SYNB1891, which synthesizes a STING agonist under hypoxic tumor conditions, demonstrated controllable immunogenicity and an acceptable safety profile in a Phase I trial, supporting the clinical feasibility of local innate immune activation and its potential for combination with systemic immunotherapies (14). The gene discussed is STING1; the disease is neoplasm.